Zhengrong Huang

Zhengrong Huang


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 April 2025 in International Immunopharmacology
Verified
Journal Article
Closed access
XZXiaoxiong Zhang
Xiaoxiong Zhang
HDHekang Du
Hekang Du
TQTao Qiu
Tao Qiu
HFHonggao Fu
Honggao Fu
JDJiawei Dai
Jiawei Dai
ZHZhengrong Huang
Zhengrong Huang

18 October 2025 in Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy
Verified
Journal Article
Closed access
XZXiaojun Zeng
Xiaojun Zeng
WCWeiqing Chen
Weiqing Chen
JYJunhan Yang
Junhan Yang
QZQinshu Zhang
Qinshu Zhang
WDWeili Deng
Weili Deng
DLDaliang Li
Daliang Li

26 December 2024 in Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy
Verified
Journal Article
Open access
JLJinpei Lin
Jinpei Lin
SLShufang Lin
Shufang Lin
ZLZengyan Lin
Zengyan Lin
ZHZhengrong Huang
Zhengrong Huang
DLDaliang Li
Daliang Li
Reactive oxygen species (ROS) play a dual role in the chemotherapy of cancer with cisplatin, providing both anti-tumor effects and contributing to drug resistance at various stages of treatment which seriously affects treatment effectiveness. The detailed mechanism of ROS is urgently necessary to be explored. To address this issue in the non-small-cell lung cancer (NSCLC) with cisplatin-resistance, a reliable assay was developed by synthesizing and characterizing an interesting near-infrared (NIR) ONOO- probe BPB with high specificity, quick response (<30 s) and excellent limitation of detection (59 nM), which was further convinced through living cell imaging techniques providing different fluorescence variation between cell and cuvette. All the results revealed that ONOO- might be a practical biomarker to comprehend the detail molecular mechanism in cisplatin-resistant A549 cells. The elevated levels of ONOO- in cisplatin-resistant A549 cells, accompanied by a significant reduction in fluorescence following the knockout of miR-125a-5p in these cells and strong fluorescence without knockout of miR-125a-5p ignoring the presence of cisplatin. Comparing with cisplatin-resistant cells, the control would provide a rational background and then showed distinct fluorescence from BPB with ONOO- toward cisplatin. This assay offers a promising tool for exploring the molecular mechanisms associated with miR-125a-5p and its potential linkage to therapeutic efficacy involving ONOO- signaling. By utilizing this innovative assay, researchers can gain valuable insights into the treatment strategies and underlying mechanisms of cisplatin-resistant cancers, which should be beneficial to the therapy of cancers.

2 June 2026 in Talanta
Verified
Journal Article
Closed access
QLQiying Lian
Qiying Lian
QWQing Weng
Qing Weng
MHMingbo He
Mingbo He
LLLi Li
Li Li
ZHZhengrong Huang
Zhengrong Huang
BLBingguo Lu
Bingguo Lu